Mark Velleca Biography and Net Worth
Dr. Mark Velleca was the Chief Executive Officer of G1 from 2014 to 2020 and remains a board member and Senior Advisor to the company. Previously, he served as Executive Vice President at the Leukemia & Lymphoma Society (LLS). Prior to LLS, Mark was a co-founder and Senior Vice President of CGI Pharmaceuticals, where he managed the company from its inception through clinical trials of multiple drug candidates. After Gilead Sciences acquired CGI, he served as a Senior Advisor to Gilead in R&D Strategy and Corporate Development.
Earlier in his career, Mark was an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine.
Mark is currently a Venture Partner at Hatteras Venture Partners, board chair at Turbine AI, and a board member at IMMvention Therapeutix.
Mark earned an M.D. and Ph.D. from Washington University in St. Louis, and a B.S. from Yale University.
What is Mark A. Velleca's net worth?
The estimated net worth of Mark A. Velleca is at least $1.45 million as of September 20th, 2022. Dr. Velleca owns 116,000 shares of G1 Therapeutics stock worth more than $1,454,640 as of September 28th. This net worth estimate does not reflect any other assets that Dr. Velleca may own. Additionally, Dr. Velleca receives a salary of $242,690.00 as Director at G1 Therapeutics. Learn More about Mark A. Velleca's net worth.
How old is Mark A. Velleca?
Dr. Velleca is currently 58 years old. There are 7 older executives and no younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics is Dr. Rajesh K. Malik Ch.B., M.B., M.D., Chief Medical Officer and Sr. VP of R&D, who is 63 years old. Learn More on Mark A. Velleca's age.
What is Mark A. Velleca's salary?
As the Director of G1 Therapeutics, Inc., Dr. Velleca earns $242,690.00 per year. There are 5 executives that earn more than Dr. Velleca. The highest earning executive at G1 Therapeutics is Mr. John E. Bailey Jr., CEO, Pres & Director, who commands a salary of $1,040,000.00 per year. Learn More on Mark A. Velleca's salary.
How do I contact Mark A. Velleca?
Has Mark A. Velleca been buying or selling shares of G1 Therapeutics?
During the last quarter, Mark A. Velleca has sold $1,281,200.00 in G1 Therapeutics stock. Most recently, Mark A. Velleca sold 20,000 shares of the business's stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $13.50, for a transaction totalling $270,000.00. Following the completion of the sale, the director now directly owns 116,000 shares of the company's stock, valued at $1,566,000. Learn More on Mark A. Velleca's trading history.
Who are G1 Therapeutics' active insiders?
Are insiders buying or selling shares of G1 Therapeutics?
In the last year, insiders at the sold shares 6 times. They sold a total of 154,218 shares worth more than $1,937,902.86. The most recent insider tranaction occured on September, 20th when Director Mark A Velleca sold 20,000 shares worth more than $270,000.00. Insiders at G1 Therapeutics own 8.1 % of the company. Learn More about insider trades at G1 Therapeutics.
Information on this page was last updated on 9/20/2022.
Mark A. Velleca Insider Trading History at G1 Therapeutics
|Transaction Date||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
G1 Therapeutics Company Overview
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
50 Day Range
2 Week Range